Autoimmune disorders result from dysregulated immune responses directed
against the body's tissues; immunotherapeutic biopolymers are becoming increasingly
important as transformational agents in this regard. These biopolymers, which
comprise organic materials like peptides and polysaccharides, function in different
ways to help the immune system's restoration to equilibrium. A noteworthy method
pertains to the control of immune cell function, wherein biopolymers augment the
functionalities of regulatory T cells while inhibiting the generation of pro-inflammatory
cytokines. Furthermore, certain biopolymers, such as hyaluronic acid and chitosan,
have anti-inflammatory qualities that are vital in lowering tissue damage and
inflammation linked to autoimmune diseases. By influencing the gut microbiota, which
has been linked to the etiology of several autoimmune disorders, these biopolymers can
also balance the immune system. The adaptability of immunotherapeutic biopolymers
is further demonstrated by their capacity to target particular pathways, such as the NFκB signaling cascade and cytokine production. Recent developments in
nanotechnology have made it possible to create delivery systems based on biopolymers
that improve the bioavailability and effectiveness of medicinal drugs. Not only does
this novel method increase therapeutic specificity, but it also reduces systemic adverse
effects that are frequently linked to traditional medications. Personalized and efficient
therapy techniques might transform the management of autoimmune diseases as
research advances and immunotherapeutic biopolymers are incorporated into clinical
practice.
Keywords: Antigen presentation, Autoimmune diseases, Gut microbiota, Immunological regulation, Immunotherapeutic biopolymers, Inflammation, Regulatory T cells.
